Human Insulin Drugs Market in Brazil by Distribution Channel, Product, and Application - Forecast and Analysis 2019-2023
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 135 Pages
Technavio's human insulin drugs market in brazil market analysis considers sales from basal insulin analog and NPH products. Our study also finds the sales of the human insulin drugs market in brazil in retail and hospital distribution channels. In 2018, the basal insulin analog segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as flexibility of timing and dosing, less fear of dose adjustment, and fewer injections with analogs to achieve their therapeutic effect will play a significant role in the basal insulin analog segment to maintain its market position. Also, our human insulin drugs market in brazil report looks at factors such as rising prevalence of diabetes in Brazil, demographic transition in Brazil, and strategic alliance. However, high cost of human insulin drugs, unknown etiology of type I diabetes, and unavailability of specific biomarkers may hamper the growth of the human insulin drugs market in brazil over the forecast period.
Brazil has undergone rapid demographic, nutritional, and epidemiological transitions, which have led to an increase in the prevalence of diabetes in this region. Currently, the youth demographic forms a significant portion of Brazil's population. Since type I diabetes affects an individual at an incredibly young age, the presence of a large younger demographic provides significant growth opportunities for vendors in the human insulin drugs market in Brazil. This demographic transition in brazil will lead to the expansion of the human insulin drugs market in brazil at a CAGR of over 5% during the forecast period.
Technological advancements are expected to be one of the key factors for the growth of the human insulin drug market size in Brazil during the forecast period. The availability of novel digital equipment and data-driven devices, such as the connected care insulin delivery system, has fueled the interest of researchers in this area. The major vendors in the market are now focusing on developing novel human insulin drugs through strategic alliances, especially by partnering with research institutes and other healthcare organizations. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the human insulin drugs market in brazil during the forecast period 2019-2023, view our report.
With the presence of several major players, the human insulin drugs market in brazil is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human insulin drugs market in brazil manufacturers, that include Biocon Ltd., Eli Lilly and Co., Novo Nordisk AS, Sanofi, and Wockhardt Ltd.
Also, the human insulin drugs market in brazil includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.